Vancomycin-resistant Enterococcus (VRE) sepsis is emerging as a significant problem in the intensive care setting. The treatment at any age is challenging, but there is a dearth of information on this infection and its treatment in the very premature infant. We describe successful treatment of persistent bacteremia caused by Enterococcus faecium with vancomycin and high-level gentamicin resistance in a 10-day-old former 23-week premature male infant. Journal of Perinatology (2009) 29, 66-68; doi:10.1038/jp.2008 Case We present the case of twin 2, male, who was born by vaginal breech delivery at 23 þ 6 weeks gestation with a birth weight of 610 g. The pregnancy was complicated by preterm labor secondary to cervical incompetence. Membranes ruptured 48 h before delivery and the mother was commenced on oral erythromycin. No intrapartum antibiotics were administered. Maternal urine and high vaginal swab at the time of rupture were clear. The infant was ventilated from birth and received a surfactant for respiratory distress syndrome. He was initially treated for 7 days with intravenous benzylpenicillin and gentamicin ( Figure 1 ). He required dopamine until day 2 of life. Central intravascular access (umbilical venous and arterial catheter) was obtained on day 1 of life. The initial blood culture was negative. The umbilical venous catheter was electively removed on day 8 of life and a peripherally inserted central catheter was placed. The umbilical arterial catheter was removed on day 9 of life. On day 10 of life he clinically deteriorated with a worsening respiratory status, severe hypotension and metabolic acidosis. A full blood count at the time had a white cell count of 6.3 Â 10 9 l À1 with 37% neutrophils and 45% bands. The immature-to-total neutrophil ratio was 0.56; platelets were 25 Â 10 9 l À1 and C-reactive protein was 24.4 mg l À1 . A white cell count 2 days earlier was 8.2 Â 10 9 l À1 .The infant was empirically commenced on vancomycin and gentamicin. A blood culture subsequently grew Enterococcus faecium that was resistant to vancomycin (VRE). This was the first VRE isolate identified in our institution. VRE was also cultured from the umbilical arterial catheter tip (>100 colonies VRE), and in a rectal swab. The antibiotic profile indicated resistance to penicillin, ampicillin, vancomycin, teicoplanin, erythromycin, ciprofloxacin, high-level gentamicin and high-level streptomycin but susceptibility to linezolid, tetracycline, quinupristin/dalfopristin, daptomycin and chloramphenicol. Once sensitivities were identified on day 11 of life, vancomycin was discontinued and linezolid was commenced and the peripherally inserted central catheter line was removed. On days 15 and 17 of life, blood cultures grew Candida parapsilosis as did the culture of the peripherally inserted central catheter line tip. Liposomal amphotericin B was added to the antibiotic regimen and all peripheral intravascular catheters were replaced. On day 18 of life, his blood culture grew a VRE, despite linezolid therapy for the previous 7 days. Work up for a source of persistent infection was undertaken. An echocardiogram was normal without evidence of vegetation. However, an intra-aortic abdominal thrombus was detected and this was presumed to be the focus of infection. The VRE isolate from day 18 of life was now noted to be resistant to quinupristin/dalfopristin (minimum inhibitory concentration ¼ 2 mg l À1 ), despite no exposure to this antibiotic. The remaining sensitivity results were unchanged. In view of the persistently positive blood cultures, chloramphenicol (10 mg kg À1 ) and gentamicin were added on day 19, with gentamicin levels kept within the high normal range.
Case
We present the case of twin 2, male, who was born by vaginal breech delivery at 23 þ 6 weeks gestation with a birth weight of 610 g. The pregnancy was complicated by preterm labor secondary to cervical incompetence. Membranes ruptured 48 h before delivery and the mother was commenced on oral erythromycin. No intrapartum antibiotics were administered. Maternal urine and high vaginal swab at the time of rupture were clear. The infant was ventilated from birth and received a surfactant for respiratory distress syndrome. He was initially treated for 7 days with intravenous benzylpenicillin and gentamicin ( Figure 1 ). He required dopamine until day 2 of life. Central intravascular access (umbilical venous and arterial catheter) was obtained on day 1 of life. The initial blood culture was negative. The umbilical venous catheter was electively removed on day 8 of life and a peripherally inserted central catheter was placed. The umbilical arterial catheter was removed on day 9 of life. On day 10 of life he clinically deteriorated with a worsening respiratory status, severe hypotension and metabolic acidosis. A full blood count at the time had a white cell count of 6.3 Â 10 9 l À1 with 37% neutrophils and 45% bands. The immature-to-total neutrophil ratio was 0.56; platelets were 25 Â 10 9 l À1 and C-reactive protein was 24.4 mg l À1 . A white cell count 2 days earlier was 8.2 Â 10 9 l À1 .The infant was empirically commenced on vancomycin and gentamicin. A blood culture subsequently grew Enterococcus faecium that was resistant to vancomycin (VRE). This was the first VRE isolate identified in our institution. VRE was also cultured from the umbilical arterial catheter tip (>100 colonies VRE), and in a rectal swab. The antibiotic profile indicated resistance to penicillin, ampicillin, vancomycin, teicoplanin, erythromycin, ciprofloxacin, high-level gentamicin and high-level streptomycin but susceptibility to linezolid, tetracycline, quinupristin/dalfopristin, daptomycin and chloramphenicol. Once sensitivities were identified on day 11 of life, vancomycin was discontinued and linezolid was commenced and the peripherally inserted central catheter line was removed. On days 15 and 17 of life, blood cultures grew Candida parapsilosis as did the culture of the peripherally inserted central catheter line tip. Liposomal amphotericin B was added to the antibiotic regimen and all peripheral intravascular catheters were replaced. On day 18 of life, his blood culture grew a VRE, despite linezolid therapy for the previous 7 days. Work up for a source of persistent infection was undertaken. An echocardiogram was normal without evidence of vegetation. However, an intra-aortic abdominal thrombus was detected and this was presumed to be the focus of infection. The VRE isolate from day 18 of life was now noted to be resistant to quinupristin/dalfopristin (minimum inhibitory concentration ¼ 2 mg l À1 ), despite no exposure to this antibiotic. The remaining sensitivity results were unchanged. In view of the persistently positive blood cultures, chloramphenicol (10 mg kg À1 ) and gentamicin were added on day 19, with gentamicin levels kept within the high normal range.
Serum levels of chloramphenicol were maintained within the recommended range of 10 to 25 mg l À1 and checked on days 3, 5, 10 and 12 of treatment. Full blood count and liver function tests remained normal. Chloramphenicol was discontinued after 2 weeks, by this time the infant was stable, the intra-aortic thrombus was shrinking in size and two negative blood cultures had been recorded. Linezolid was continued for a total of 6 weeks with stable full blood count. Serial ultrasound scans over this time showed a gradual resolution of the intra-abdominal clot. No lumbar puncture was performed during this time. Urine examination was unremarkable, and a renal ultrasound done at the time was normal.
The infant remained ventilator-dependent with high ventilatory requirements and evidence of evolving severe changes of chronic lung disease on serial chest X-rays. He also sustained bilateral grade 3 intraventricular hemorrhages, with an associated cerebellar hemorrhage. Weight gain remained suboptimal, despite tolerating 170 ml kg À1 of expressed breast milk with added fortifier orally for 25 days after discontinuing all antibiotics. The infant had a sudden acute respiratory decompensation and died despite aggressive resuscitation with reintubation and adrenaline. Post-mortem examination confirmed no evidence of VRE or Candida infection, including central nervous system involvement, and found no evidence of an intra-abdominal clot. Cause of death was concluded to be severe chronic lung disease secondary to extreme prematurity.
Discussion
Enterococci are part of the normal gastrointestinal flora. They are implicated in a range of infections including urinary tract infection, bacteremia and endocarditis. VRE were first identified in 1985 and have now been identified worldwide. They now account for 31.7% of all E. faecium bacteremia cases reported in Ireland in 2005. 1 Treatment of VRE sepsis in all age groups is challenging because of the limited therapeutic options, because of both intrinsic and acquired antibiotic resistance. We believe this is the first and only reported case of VRE sepsis treated successfully in an extremely low birth-weight infant with a corrected gestational age of 25 þ 2 weeks at the time of onset of infection. A review of the literature yielded four case reports of premature extremely low birth-weight infants, w/VRE 'sepsis'. In 2003, Ang et al. 2 reported a case of successfully treated VRE endocarditis in a 4 1/2-month-old 26-week premature infant using linezolid. The infant received intravenous linezolid for a total of 7 weeks, followed by oral treatment with the same dosage (15 mg kg À1 every 8 h) for another 2 weeks. 2 However, this infant has a corrected gestational age of approximately 4 weeks post term and so is not really comparable with our case. Two other cases reported by Hoehn et al., 3 included a 6-weekold 24-week premature infant and a 12-day-old 30-week premature infant, both of whom were treated with linezolid, and in both cases the VRE was successfully eradicated. It can be noted that, however, neither of their two cases had positive blood cultures. In the first infant, E. faecium was isolated from intact skin, tracheal aspirates and the tip of a chest tube. In the second infant, E. faecuim was isolated in swab cultures taken from the peritoneal cavity in association with a bowel resection done secondary to necrotizing enterocolitis.
The first infant received 16 days of intravenous linezolid and the latter received 14 days of intravenous linezolid. 3 However, the latter two cases never grew Enterococcus faecium in their blood cultures, so, once again these cannot be considered similar to our case.
Two further cases reported by Klingkowski et al. VRE bacteremia in ELBW infant N Hapnes et al 28-week premature infant. In both of these infants, E. faecium was isolated in swab cultures taken intraoperatively secondary to necrotizing enterocolitis. Again, neither of these infants had positive blood cultures. Linezolid was initially chosen for therapy in our infant because of the extensive experience that has accrued in recent years in the pediatric population, including neonates; 4 however, very little is known about the use of linezolid in critically ill very low birthweight infants, and few data are available. 2, [5] [6] [7] [8] When the baby developed persistent VRE sepsis, despite linezolid therapy for 5 days, removal of all central lines and replacement of all peripheral intravascular catheters, there were a number of therapeutic options to consider, none of which was ideal. Synergy with an aminoglycoside could not be used because of high-level resistance. Neither could therapy with quinupristin/dalfopristin be considered, as the second blood stream isolate was resistant. Although the VRE isolate was susceptible to the new lipopeptide antibiotic, daptomycin (minimum inhibitory concentration ¼ 2 mg l À1 , using Clinical and Laboratory Standards Institute criteria), we chose to reserve daptomycin for use if other options failed as the minimum inhibitory concentration was close to the breakpoint (4 mg l À1 ), its efficacy against Enterococci has not been established 9 and there are no published reports of experience in neonatal or pediatric patients. Side effects of tetracycline are well known in the pediatric population and therefore this drug was also reserved for use if other options failed. Adverse effects from chloramphenicol are well recognized and include serious blood disorders and gray baby syndrome in neonates. 10 Nonetheless, chloramphenicol is a potent broad-spectrum antibiotic that has been used to successfully treat many invasive infections, including meningitis. With caution, we chose to add chloramphenicol to linezolid therapy, because of its well-known ability to penetrate many body sites from which other antibiotics are often excluded, and this included infected thrombi. We closely monitored hematological, renal and hepatic indices and chloramphenicol levels. The infant had an excellent clinical and microbiological response to this combination therapy, with three negative blood cultures, normalizing white cell count and C-reactive proteins, and resolving thrombus on ultrasound. It must be acknowledged that the presence of an infected thrombus may have been as important a contribution to persistent bacteremia in this case as the antimicrobial resistance of the isolate. Nevertheless, this case highlights the difficulty in managing resistant organisms and sepsis in extremely low birth-weight infants. Following this case our unit now routinely screens all infants for VRE once weekly.
Conclusion
The importance of the case is that persistent VRE sepsis, secondary to an umbilical catheter line infection with a presumed infected intra-aortic thrombus, was successfully treated in an extremely low birth-weight infant with a corrected gestational age of 25 þ 2 weeks at the time of the onset of infection using the unorthodox combination of two bacteriostatic antibiotics, linezolid and chloramphenicol. It is essential that continuous reporting of these cases occur so that clinicians caring for critically ill extremely premature infants are kept abreast of the safest treatment options available.
